Login to Your Account

Vicuron Stock Takes Tumble On FDA Antifungal Decision

By Randall Osborne

Tuesday, May 25, 2004
News from the FDA that Vicuron Pharmaceuticals Inc.'s new drug application for anidulafungin does not support a label for esophageal candidiasis sent the company's stock reeling Monday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription